Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$104.8MCash on Hand
21.7mo Cash Runway
Follow PEPG by emailGet an email when PEPG reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PEPG, unsubscribe in one click. Privacy
📣 What PEPG Says Is Next
in January 2027 · “PepGen also expects to report interim clinical data at 5 mg/kg and safety data at 10 mg/kg from the open-label extension study in January 2027.”
Company press release, Nov 10, 2026 · SEC filing
first half of 2027 · PGN-EDODM1: “We are deeply grateful to the FREEDOM2 investigators, study teams, participants, and their families for their dedication and commitment to this study.” The 12.5 mg/kg cohort of FREEDOM2 is fully enrolled, with participants having received up to three doses and clinical results expected in the first half of 2027.”
Company press release, Nov 10, 2026 · SEC filing
second half of 2027 · PGN-EDODM1: “PGN-EDODM1 Regulatory Updates: o Data from the FREEDOM2 and FREEDOM-OLE studies ( NCT07220603 ) are expected to support an end-of-Phase 2 (EOP2) meeting in the second half of 2027 pending removal of the partial clinical hold. o In March 2026, PepGen announced that the U.S. Food and Drug Administration (FDA) issued a partial clinical hold on the FREEDOM2 study citing nonclinical findings in mice.”
Company press release, Nov 10, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Financing PepGen is offering 25,000,000 shares of common stock at $5.00 per share, for gross proceeds of $125,000,000 before expenses. Underwriters have a 30-day option to buy up to 3,750,000 additional shares. Delivery is expected on or about November 13, 2026. Form 424B5 · SEC filing
Nov 12, 2026 ·
Financing PepGen priced an underwritten offering of 25,000,000 common shares at $5.00 per share, with a 30-day option for 3,750,000 more shares. Net proceeds are expected to be about $116.9 million, or about $134.5 million if the option is fully exercised. Closing is expected on or about November 13, 2026. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 10, 2026 ·
Clinical trial Reported Q3 2026 results with $104.8M cash, funding operations into 2028, and net loss of $19.4M. Announced positive 10 mg/kg FREEDOM2-DM1 cohort data with 46.5% mean splicing correction; DSMB advanced the study to the 12.5 mg/kg cohort, with results expected 1H 2027. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Financing PepGen Inc. filed a preliminary prospectus supplement for a proposed $125,000,000 offering of common stock and pre-funded warrants. The stock closed at $4.61 on November 10, 2026. Pricing terms are blank, and underwriters are Leerink Partners, Stifel and Guggenheim Securities. Form 424B5 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2027 · Phase 2 · Recruiting · A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 Registry primary completion date, not a results date
Jan 2029 · Phase 2 · Recruiting · An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PEPG holds $104.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $14.5M/quarter from operations,
an estimated runway of 21.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:18 · Low
Cash runway 22 months +8
ATM program on file since May 2026 +15
Shelf registration (S-3, May 2026) +10
Company says cash lasts into 2028 -5We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our currently planned operations into 2028.10-Q, Nov 2026
Raised after last reported balance sheet (Nov 2026) -10
Recent financing filings on SEC EDGAR:
Nov 12, 2026 · Underwritten offering, $125M · 424B5
Share count 69,261,282 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PEPG picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PEPG and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.